Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 6/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2539034 | 0.75 | ALDH1A1 (0.41) | ALDH1A1LMNACA2CA1MAPK1 | |
| SCHEMBL14125822 | 0.74 | ALDH1A1 (0.44) | ALDH1A1LMNACA2CA1MAPK1 | |
| SCHEMBL423728 | 0.74 | ALDH1A1 (0.44) | ALDH1A1LMNACA2CA1MAPK1 | |
| SCHEMBL11832228 | 0.74 | ALDH1A1 (0.44) | ALDH1A1LMNACA2CA1MAPK1 | |
| SCHEMBL12209116 | 0.74 | ALDH1A1 (0.44) | ALDH1A1LMNACA2CA1MAPK1 | |
| SCHEMBL6909027 | 0.74 | ALDH1A1 (0.33) | ALDH1A1LMNACA2CA1MAPK1 | |
| SCHEMBL1195884 | 0.74 | TSHR (0.38) | ALDH1A1LMNACA2CA1MAPK1 | |
| SCHEMBL28071184 | 0.74 | HTT (0.42) | DNM1 | |
| SCHEMBL11817761 | 0.72 | ALDH1A1 (0.46) | ALDH1A1LMNACA2CA1MAPK1 | |
| SCHEMBL4160464 | 0.72 | CA2 (0.35) | ALDH1A1LMNACA2CA1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2402302-B1 | PROCESS FOR PRODUCING ETHER COMPOUND | KAO CORP (JP) | 2017-11-22 | — | — | EP | disclosed |
| US-20120004470-A1 | PROCESS FOR PRODUCING ETHER COMPOUND | KAO CORPORATION (JP) | 2012-01-05 | — | — | US | disclosed |
| EP-2402302-A1 | PROCESS FOR PRODUCING ETHER COMPOUND | Kao Corporation (JP) | 2012-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004470-A1 | PROCESS FOR PRODUCING ETHER COMPOUND | CYP4F11, CYP4A11, RPS14 | ALDH1A1 2958/4885LMNA 3682/4885CA2 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.